Novavax shares surge on promising H1N1 results; Regeneron CEO touts upcoming results from aflibercept PhIII;

 @FierceBiotech: Merck KGaA puts Stimuvax trial on hold after encephalitis strikes. Report | Follow @FierceBiotech

 @JohnCFierce: Carl Icahn is having a heck of a week in biotech. Genzyme black eye, talking up Biogen sale. And it's only Wednesday | Follow @JohnCFierce

>  Shares of Novavax surged this morning when the vaccine developer announced that the first phase of its two-phase study of a new H1N1 jab produced positive results. The second stage will recruit 3,500 subjects in Mexico. Novavax release | Story

> Regeneron CEO Leonard Schleifer essentially talked up the value of his shares yesterday. Researchers project late-stage data on cancer drug aflibercept will arrive in the first half of 2011 and he speculates that it could show a safety advantage over Avastin. Shares rose 5.5 percent Tuesday afternoon. Report

> Following a news story related to its plans to raise fresh funds, France's Transgene confirmed that it intends to raise 100 million to €150 million. The developer added that it has yet to decide on the best timing for the move. Report

> RXi Pharmaceuticals, a subsidiary of CytRx, plans to buy back 675,000 of its own shares from CytRx at $5.70 a share. That's a 30 percent discount on Monday's close. Story

> Wilex has confirmed an equity line that will provide up to €20 million in financing. Release

> Sanofi-Aventis and Bristol-Myers Squibb said their Duoplavin-Duocover combinbation tablet has been approved in the European Union. Story

And Finally... Researchers from the Harvard School of Public Health in collaboration with researchers from the Institute for Health Metrics and Evaluation at the University of Washington estimate that smoking, high blood pressure, elevated blood glucose and overweight and obesity currently reduce life expectancy in the U.S. by 4.9 years in men and 4.1 years in women. Report

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.